Drug Profile

JP 2266

Alternative Names: JP-2266

Latest Information Update: 27 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jeil Pharmaceutical
Class Antihyperglycaemics; Small molecules
Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Nov 2023 Jeil Pharmaceutical plans a phase II trial for Type 2 diabetes mellitus (In adults, In the elderly) in South Korea (PO) (NCT06144788)
21 Apr 2023 Phase-I clinical trials in Type 1 diabetes mellitus (Combination therapy) in South Korea (PO) (Jeil pharmaceutical's pipeline, April 2023)
28 May 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in South Korea (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com